Array BioPharma is involved in the discovery, development and commercialisation of targeted small molecule medicines for the treatment of cancer and other high-burden diseases. The company sells Braftovi
The post Pfizer to buy Array BioPharma for £9.06bn appeared first on Pharmaceutical Business review.
Original Article: Pfizer to buy Array BioPharma for £9.06bn